ANI Pharmaceuticals (ANIP)

[Just the facts maam]

So on October 3, 2017, Dentons stops prosecuting the patent when asked to elect which condition to review reducing CV events or reducing Breast Cancer events and make separate application for the other.

While Przybyl wa still CEO and Brown was still Chairman, they get Orrick, Herrington & Sutcliffe LLP, to represent ANIP as early as the third quarter of 2018, when they acquired Wellspring Pharma.

Since 2018, it looks like Orrick, Herrington & Sutcliffe LLP has represented or counseled ANIP in everything except the Merger with Novitium. According the releases Novitium was advised by Orrick, Herrington & Sutcliffe LLP and ANIP was advised by Hubbard Hughes & Reed LLP. Even the most recent S8 filing Orrick, Herrington & Sutcliffe LLP acted as counsel for ANIP.

Makes me wonder why Orrick, Herrington & Sutcliffe LLP advised Novitium instead of ANIP.

In the FTC required divestiture to approve the merger, the Agreement Containing Consent Orders had Orrick, Herrington & Sutcliffe LLP acting as counsel for Novitium and Esjay LLC , where as Latham & Watkins LLP acted as counsel for ANIP. With all the lawyers at Hubbard Hughes & Reed LLP had working for ANIP on the merger, they farm out work to Latham & Watkins LLP. Don’t get me wrong Latham & Watkins LLP are among the best, they successfully defended Humira against biosimilar competition in the US until January 2023 and represented Allergan in their buyout by AbbVie . But the legal head count just keeps rising. Hard to believe, for a $210 million deal.

Agreement Containing Consent Orders

Hopefully, it will al make sense shortly.

GLTA